Metabolic dysfunction associated fatty liver disease identifies subjects with cardiovascular risk better than non‐alcoholic fatty liver disease

• Published in: Liver international Vol. 43; no. 3; pp. 608 - 625
• Main Authors: Chun, Ho Soo, Lee, Minjong, Lee, Jae Seung, Lee, Hye Won, Kim, Beom Kyung, Park, Jun Yong, Kim, Do Young, Ahn, Sang Hoon, Lee, Yong‐Ho, Kim, Ji‐Hye, Kim, Seung Up
• Format: Journal Article
• Language: English
• Published: United States Wiley Subscription Services, Inc 01.03.2023
• Subjects: Arteriosclerosis; Aspartate aminotransferase; Aspartate Aminotransferases; Atherosclerosis; cardiovascular disease; Cardiovascular Diseases; Fatty liver; Fibrosis; Health risks; Heart Disease Risk Factors; Heart diseases; Humans; Liver; Liver Cirrhosis; Liver diseases; liver fibrosis; metabolic dysfunction‐associated fatty liver disease; Metabolism; Non-alcoholic Fatty Liver Disease; Population studies; Risk Factors; Subgroups; Transaminases; cardiovascular disease; liver fibrosis; metabolic dysfunction-associated fatty liver disease; non-alcoholic fatty liver disease

Background and Aims Cardiovascular disease (CVD) is the main cause of mortality in subjects with non‐alcoholic fatty liver disease (NAFLD). We investigated the association between CVD risk and metabolic dysfunction‐associated fatty liver disease (MAFLD) or NAFLD and the influence of significant live...